RNLX Renalytix AI ADS

Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference

Renalytix to Present at H.C. Wainwright 24th Annual Global Investment Conference

NEW YORK and SALT LAKE CITY, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference to be held September 12-14, 2022. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company’s website at beginning at 7:00 a.m. Eastern Time on September 12, 2022.

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory-developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D with early CKD stages 1-3. We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit .

For further information, please contact:

Renalytix plc 
James McCullough, CEOVia Walbrook PR
  
Stifel (Nominated Adviser, Joint Broker)Tel: 020 7710 7600
Alex Price / Nicholas Moore 
  
Investec Bank plc (Joint Broker)Tel: 020 7597 4000
Gary Clarence / Daniel Adams 
  
Walbrook PR LimitedTel: 020 7933 8780 or 
Paul McManus / Lianne Applegarth / Alice WoodingsMob: 07980 541 893 / 07584 391 303 / 07407 804 654
  
CapComm PartnersTel: 415-389-6400 or
Peter DeNardo

 

                                          



EN
08/09/2022

Underlying

RNLXRenalytix AI ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Renalytix AI ADS

 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Commencement of trading on OTCQB in the United States

Commencement of trading on OTCQB in the United States Renalytix plc American Depository Shares (ADSs) begin trading on OTCQB Venture Market under symbol “RNLXY” effective from Market Open on October 8, 2024 LONDON and NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that as previously disclosed regarding its intention to move listing of its American Depo...

October 8, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix and Steno Diabetes Center Announce Precision Medicine Collab...

Renalytix and Steno Diabetes Center Announce Precision Medicine Collaboration Marking First Expansion for KidneyIntelX Platform Beyond US LONDON and NEW YORK, July 11, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces a collaboration with the Steno Diabetes Center (‘Steno’), Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chro...

July 11, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard t...

Renalytix Submits Hearing Request to Nasdaq Hearings Panel in Regard to Staff Delisting Determination Throughout the hearings process and pending the Panel’s decision, the Company’s ADSs will continue trading on The Nasdaq Global Market under the symbol “RNLX” LONDON and NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: RNLX) (LSE: RENX) announces that it has formally submitted a hearing request to the Nasdaq Hearings Panel (the “Panel”), which request has now stayed the suspension of the Company's securities pending the Panel's decision as described below. Throughout the hearings p...

June 27, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Medicare Issues Final Coverage Determination for kidneyintelX.dkd

Medicare Issues Final Coverage Determination for kidneyintelX.dkd Company has Achieved Prerequisites for Growing Test Adoption with FDA Authorization, Clinical Outcomes Data, Inclusion in Clinical Guidelines, and Broad Insurance Coverage LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) --  (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare issued a final Local Coverage Determination ("LCD") for the Company's kidneyintelX.dkd testing. The final LCD can be accessed at , and is effective for dates of service on or after August 1, 2024. The established Medicare price for...

June 14, 2024 1 EN
 PRESS RELEASE
Free
RNLX Renalytix AI AD...

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2...

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024 LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of a Medicare coverage...

May 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch